Argen X Stock Quote ARGX - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

629.00

Bid

620.00

Ask

632.00

Volume

93,112

617.80 Day's Range 635.20

322.50 52 Week Range 635.20

Market Cap

37.233B

Previous Close

609.60

Open

622.00

Last Trade

200

629

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

59,047

Shares Outstanding

59,194,000

Dividend Yield

PE Ratio

-126.19

Earnings Per Share (EPS)

-4.98

Revenue

1.27B

Net Profit

-295.05M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.argenx.com

Headquarters

Amsterdam, North Holland, Nld

Founded

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 609.60 €. Over the last year, Argen X shares have traded in a share price range of 322.50 € to 635.20 €.

Argen X currently has 59,194,000 shares outstanding. The market capitalization of Argen X is 36.08 € billion. Argen X has a price to earnings ratio (PE ratio) of -126.19.

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first...

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	32	5.36013400335	597	635.2	593.6	46284	609.8710382	DE
4	50.2	8.67311679337	578.8	635.2	577.4	54724	600.76700899	DE
12	127.6	25.4487435181	501.4	635.2	493.6	59047	566.79682136	DE
26	225.1	55.7316167368	403.9	635.2	400.2	59212	510.6051257	DE
52	265.5	73.0398899587	363.5	635.2	322.5	59884	433.73677963	DE
156	334.4	113.509843856	294.6	635.2	224.1	64999	379.83407885	DE
260	488.6	348.005698006	140.4	635.2	93.05	74183	300.9784829	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?

The current share price of Argen X is 629.00 €

How many Argen X shares are in issue?

Argen X has 59,194,000 shares in issue

What is the market cap of Argen X?

The market capitalisation of Argen X is EUR 36.08B

What is the 1 year trading range for Argen X share price?

Argen X has traded in the range of 322.50 € to 635.20 € during the past year

What is the PE ratio of Argen X?

The price to earnings ratio of Argen X is -126.19

What is the cash to sales ratio of Argen X?

The cash to sales ratio of Argen X is 29.35

What is the reporting currency for Argen X?

Argen X reports financial results in USD

What is the latest annual turnover for Argen X?

The latest annual turnover of Argen X is USD 1.27B

What is the latest annual profit for Argen X?

The latest annual profit of Argen X is USD -295.05M

What is the registered address of Argen X?

The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB

What is the Argen X website address?

The website address for Argen X is www.argenx.com

Which industry sector does Argen X operate in?

Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GNROGeNeuro SA	0.146 € (114.08%)	1.83M
MLCLPColipays	1.30 € (109.68%)	4
ABAb Science	2.105 € (67.06%)	2.68M
MLWEYWeya	0.0265 € (47.22%)	74.61k
MLSRPSpeed Rabbit Pizza	30.80 € (38.74%)	193
ALCYBCybergun	0.0001 € (-50.00%)	25.64M
CFNCofina SGPS SA	18.35 € (-33.99%)	2.47k
ALBOOBOOSTHEAT	0.111 € (-19.57%)	99
MCPGrupo Media Capital Sgps Sa	1.62 € (-19.00%)	300
OXUROxurion NV	0.242 € (-13.57%)	109.17k
ATOAtos SE	0.0022 € (-8.33%)	1.48B
ALCYBCybergun	0.0001 € (-50.00%)	25.64M
BCPBanco Comercial Portugues SA	0.461 € (-2.37%)	24.08M
ALHPIHopium SA	0.0044 € (-4.35%)	15.22M
INGAING Groep NV	15.316 € (-0.27%)	12.28M